Epoprostenol for Injection in Patients With Pulmonary Arterial Hypertension

PHASE3CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

June 1, 2011

Primary Completion Date

June 1, 2015

Study Completion Date

July 1, 2015

Conditions
Pulmonary Arterial Hypertension
Interventions
DRUG

Epoprostenol

Administered by continuous intravenous infusion via a central venous catheter; using an ambulatory infusion pump. The dose and infusion rate of EFI may be adjusted throughout the study in order to balance tolerability and maximum clinical benefit

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Chiltern International Ltd.

INDUSTRY

collaborator

Effi-Stat

OTHER

lead

Actelion

INDUSTRY